Prostate cancer immune study withdrawn before starting
NCT ID NCT03274778
First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study was designed to see if the drug ruxolitinib could change immune cells in prostate tumors. Men with prostate cancer would take the drug for 28 days before surgery to remove the prostate. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.